Buchanan FDA Shareholder William A. Garvin and Associate Tina Hu-Rodgers co-authored an article in coordination with the 2015 AIPLA Annual Meeting. Their article, titled "Biosimilars: A New Breed of Generic Product," provided an overview regarding the regulatory status of biosimilars; specifically, how biosimilars are treated differently than generic drugs at the federal and state level and how this will likely impact the development of biosimilar products in the long term. 

Garvin also gave a presentation on this topic at the AIPLA meeting -- learn more here.